Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic.

Published

Journal Article (Review)

PURPOSE OF REVIEW: This article discusses glucagon-like peptide 1 physiology and its various sites of action beyond the incretin effect and highlights recent findings (2005 and 2006). RECENT FINDINGS: Glucagon-like peptide 1 is a physiological incretin in humans and promotes insulin secretion after nutrient ingestion. It is secreted from intestinal L cells after meals and may be partially responsible for the improved glycemic control and weight loss after bariatric surgery. In vivo, glucagon-like peptide 1 is quickly degraded by dipetidyl peptidase IV to glucagon-like peptide 1(9-36), which has unclear physiologic activity. Glucagon-like peptide 1 and its specific receptor are also expressed in the brain, and central nervous system. Glucagon-like peptide 1 can reduce food intake, mediate toxic illness responses and control muscle and liver glucose disposal. In the heart, glucagon-like peptide 1 receptor activation improves cardiac hemodynamics in patients following angioplasty and has a beneficial effect on myocardial function in heart failure and postischemic animal models. Finally, glucagon-like peptide 1 augments islet mass and recent studies have identified cellular mechanisms by which glucagon-like peptide 1 receptor signaling affects this process. SUMMARY: Glucagon-like peptide 1 is emerging as a regulatory factor with a broad range of actions related to substrate and energy metabolism. With the recent development of medications based on glucagon-like peptide 1 receptor signaling for diabetes treatment, these new findings suggest the promise of further application of this system for the treatment of other conditions such as obesity and cardiovascular disease.

Full Text

Duke Authors

Cited Authors

  • Aulinger, B; D'Alessio, D

Published Date

  • February 2007

Published In

Volume / Issue

  • 14 / 1

Start / End Page

  • 68 - 73

PubMed ID

  • 17940423

Pubmed Central ID

  • 17940423

Electronic International Standard Serial Number (EISSN)

  • 1752-2978

Digital Object Identifier (DOI)

  • 10.1097/MED.0b013e328013e79e

Language

  • eng

Conference Location

  • England